1993PubMedRequires access

Streptozotocin and alloxan are comparable agents in the diabetic model of impaired wound healing.

D. S. Covington, Hui Xue, Roland P. Pizzini, Kevin P. Lally, Richard J. Andrassy

Open publisher page 24 citations

Abstract

This study compares the drugs Streptozotocin (STZ) and Alloxan (ALN) in the diabetic wound healing model to determine the effect of their diverse immunologic and metabolic activity upon wound collagen and collagenase. Levels of hydroxyproline (as a measure of collagen) and collagenase were determined in polytetrafluorethylene (PTFE) wound cylinders harvested from STZ and ALN-diabetic rats and nondiabetic controls on post-operative days 5, 10 and 20. Animals treated with STZ and ALN had significantly less hydroxyproline on day 5 compared to control rats (p < 0.05). However, no difference was noted on days 10 and 20 between these two agents and controls, or between STZ and ALN at any time in the experiment. Despite their markedly dissimilar side effects, we conclude that either drug is appropriate in the diabetic wound healing when determining wound collagen and collagenase activity in this setting.

About this research paper

What this paper is about

This study compares the drugs Streptozotocin (STZ) and Alloxan (ALN) in the diabetic wound healing model to determine the effect of their diverse immunologic and metabolic activity upon wound collagen and collagenase. Levels of hydroxyproline (as a measure of collagen) and collagenase were determined in polytetrafluorethylene (PTFE) wound cylinders harvested from STZ and ALN-diabetic rats and nondiabetic controls on post-operative days 5, 10 and 20. Animals treated with STZ and ALN had significantly less hydroxyproline on day 5 compared to control rats (p < 0.05). However, no difference was noted on days 10 and 20 between these two agents and controls, or between STZ and ALN at any time in the experiment. Despite their markedly dissimilar side effects, we conclude that either drug is appropriate in the diabetic wound healing when determining wound collagen and collagenase activity in this setting.

Why it matters

OpenAlex reports 24 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This study compares the drugs Streptozotocin (STZ) and Alloxan (ALN) in the diabetic wound healing model to determine the effect of their diverse immunologic and metabolic activity upon wound collagen and collagenase. Levels of hydroxyproline (as a measure of collagen) and collagenase were determined in polytetrafluorethylene (PTFE) wound cylinders harvested from STZ and ALN-diabetic rats and nondiabetic controls on post-operative days 5, 10 and 20. Animals treated with STZ and ALN had significantly less hydroxyproline on day 5 compared to control rats (p < 0.05). However, no difference was noted on days 10 and 20 between these two agents and controls, or between STZ and ALN at any time in the experiment. Despite their markedly dissimilar side effects, we conclude that either drug is appropriate in the diabetic wound healing when determining wound collagen and collagenase activity in this setting.

Key concepts: Hydroxyproline, Collagenase, Streptozotocin, Alloxan, Wound healing, Diabetes mellitus, Medicine, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Streptozotocin and alloxan are comparable agents in the diabetic model of impaired wound healing. — Research Paper | ScholarLens